In addition, camrelizumab in combination with apatinib (a selective vascular endothelial growth factor receptor-2 [VEGFR-2] inhibitor) and chemotherapy (liposomal paclitaxel and nedaplatin) exhibited anti-tumor activity as the first-line treatment in patients with advanced ESCC [10]. This evidence concerns the gene KDR and esophageal squamous cell carcinoma.